Effect of chronic kidney disease on macrophage cholesterol efflux

Meier, Sabine M.; Wultsch, Anna; Hollaus, Marianne; Ammann, Markus; Pemberger, Elisabeth; Liebscher, Felix; Lambers, Brigitte; Fruhwürth, Stefanie; Stojaković, Tatjana; Scharnagl, Hubert; Schmidt, Alice; Springer, Alexander; Becker, Julia Powers; Aufricht, Christoph; Handisurya, Ammon; Kapeller, Stefan; Röhrl, Clemens; Stangl, Herbert; Strobl, Wolfgang

doi:10.1016/j.lfs.2015.06.005

Cited by 26 publications

(25 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the growing realisation that reductions in cholesterol cannot contribute to an HDL‐mediated increased CVD risk in patients with ESRD, other explanations have been sought in studies of HDL functions. Although reverse cholesterol transport remains the preferred explanation of how HDL may reduce CVD risk, a recent study suggests that this is not affected by CKD. Cholesterol efflux is reduced in haemodialysis patients but this appears to be related to severe reductions in apoAI concentrations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High‐density lipoprotein from end‐stage renal disease patients exhibits superior cardioprotection and increase in sphingosine‐1‐phosphate

Brinck

Thomas

Brulhart‐Meynet

et al. 2017

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Plasma S1P (lmol/L) 0. cholesterol transport remains the preferred explanation of how HDL may reduce CVD risk, a recent study 24 suggests that this is not affected by CKD. Cholesterol efflux is reduced in haemodialysis patients 5,24 but this appears to be related to severe reductions in apoAI concentrations.…”

Section: Pvaluementioning

confidence: 99%

High‐density lipoprotein from end‐stage renal disease patients exhibits superior cardioprotection and increase in sphingosine‐1‐phosphate

Brinck

Thomas

Brulhart‐Meynet

et al. 2017

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Although, HDL is the only lipoprotein in that serum, there are many other components including albumin, cytokines, haptoglobin and insulin that could affect cholesterol removal. Besides, the measurement of cholesterol removal mediated by apo B-depleted serum mitigates variations in HDL cholesterol level that are frequently altered in DM and DKD [42,43] .…”

Section: Discussionmentioning

confidence: 99%

HDL-proteome enrichment with apolipoprotein A-IV compensates for HDL loss of function in diabetes mellitus kidney disease

Santana

Lira

Pinto

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and aims: Diabetes mellitus kidney disease (DKD) is associated with lipid derangements worsening kidney function and enhancing cardiovascular (CV) risk. The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CV complications bringing up the participation of untraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in HDL proteome and functionality. We analyzed HDL composition, proteome, chemical modification and functionality in non-dialytic DKD subjects categorized according to glomerular filtration rate (GFR) and urinary albumin excretion rate (AER). Methods: DKD individuals were divided in GFR > 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and GFR < 60 plus A3 (n = 25) and matched by age with control subjects (GFR > 60; n = 8). Results: Targeted proteomic analyses quantified 29 proteins associated with HDL in all groups, although only 2 were more expressed in GFR < 60 + A3 group in comparison to controls: apolipoprotein D (apo D) and apo A-IV. HDL from GFR < 60 + A3 presented higher levels of total AGEs, pentosidine and carbamoylation (1.2, 1.1 and 4.2 times, respectively) and a reduced ability in removing 14C-cholesterol from macrophages (33%) in comparison to controls. The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups but HDL from GFR < 60 + A3 presented a higher ability in inhibiting the secretion of IL6 and TNF alpha (95%) in LPS-elicited macrophages in comparison to control group. Conclusion: The increment in apo A-IV that presents many antiatherogenic actions seems to counteract the HDL chemical modification by AGE and carbamoylation and its increment in apo D that occurred in well-established DKD.

show abstract

“…In addition, measurement of cholesterol removal mediated by apoB-depleted serum hides the variations in HDL cholesterol levels that are frequently altered in DM and DKD [49,50].…”

Section: Discussionmentioning

confidence: 99%

Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis

Santana

Lira

Pinto

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and aims: Diabetic kidney disease (DKD) is associated with lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk. The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality. The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER). Methods: Individuals with DKD were divided into eGFR>60 mL/min/1.73 m2 plus AER stages A1 and A2 (n=10) and eGFR<60 plus A3 (n=25) and matched by age with control subjects (eGFR>60; n=8). Results: Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR<60+A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV. HDL from the eGFR<60+A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls. The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR<60+A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group. Conclusion: The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.

show abstract

Effect of chronic kidney disease on macrophage cholesterol efflux

Cited by 26 publications

References 36 publications

High‐density lipoprotein from end‐stage renal disease patients exhibits superior cardioprotection and increase in sphingosine‐1‐phosphate

High‐density lipoprotein from end‐stage renal disease patients exhibits superior cardioprotection and increase in sphingosine‐1‐phosphate

HDL-proteome enrichment with apolipoprotein A-IV compensates for HDL loss of function in diabetes mellitus kidney disease

Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis

Contact Info

Product

Resources

About